Optimizing hypertension management in clinical practice (Q36568468)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on 10 August 2006

Language	Label	Description	Also known as
English	Optimizing hypertension management in clinical practice	scientific article published on 10 August 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

1 reference

Europe PubMed Central

Optimizing hypertension management in clinical practice (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

author name string

Heagerty A

1

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

publication date

10 August 2006

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Journal of Human Hypertension

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

841-849

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

How important is optimal blood pressure control?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Recent hypertension trials: implications and controversies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Update on the management of hypertension: recent clinical trials and the JNC 7.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

The essence of effective treatment and compliance is simplicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Controversies in hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Atenolol in hypertension: is it a wise choice?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Angiotensin-II receptor blockers: benefits beyond blood pressure reduction?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Angiotensin II and trials of cardiovascular outcomes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Adverse effects of the angiotensin-converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Angiotensin II receptor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

More heat to support aggressive blood pressure lowering: the FEVER study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

The ongoing telmisartan alone and in combination with ramipril global endpoint trial program

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

The importance of blood pressure control in the patient with diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Compliance and persistence with newer antihypertensive agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Rationale for combination therapy in the management of hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Combination drug treatment of hypertension: have we come full circle?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Effects of valsartan/hydrochlorothiazide and amlodipine on ambulatory blood pressure and plasma norepinephrine levels in high-risk hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-gro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Optimizing medication adherence in older persons with hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Improving patient compliance: a major goal in the management of hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Patient adherence and medical treatment outcomes: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Patient Adherence With Amlodipine, Lisinopril, or Valsartan Therapy in a Usual-Care Setting

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Practice Guidelines For Primary Care Physicians

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

21 January 2018

The determinants of hypertension awareness, treatment, and control in an insured population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

based on heuristic

inferred from DOI database lookup

Blood-pressure control in the hypertensive population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment for Newly Diagnosed Hypertension: Patterns of Prescribing and Antihypertensive Effectiveness in the UK

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

based on heuristic

inferred from DOI database lookup

Control of high blood pressure in primary health care

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

based on heuristic

inferred from DOI database lookup

Physicians' knowledge, attitudes, and practice of pharmacologic treatment of hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypertension guidelines and their limitations--the impact of physicians' compliance as evaluated by guideline awareness

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

based on heuristic

inferred from DOI database lookup

Physician-related barriers to the effective management of uncontrolled hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

based on heuristic

inferred from DOI database lookup

Physician-related barriers to hypertension management

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

based on heuristic

inferred from DOI database lookup

Lifestyle modification to improve blood pressure control in individuals with diabetes: is physician advice effective?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

based on heuristic

inferred from DOI database lookup

Longitudinal Study on Hypertension Control in Primary Care: The Insubria Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

based on heuristic

inferred from DOI database lookup

Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

based on heuristic

inferred from DOI database lookup

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

based on heuristic

inferred from DOI database lookup

Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.JHH.1002079

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36568468&oldid=2199043117"